ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
AMXT1501-102: A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients with Cancer
Protocol ID
AMXT1501-102
Condition/s
DIPG
DMG
Diagnosis Stage
New diagnosis
Relapse/refractory
Location
NSW
Sponsor
Aminex Therapeutics, Inc.
Links
External Registry ≫
Trial Status
Open
Sites
Sydney Children's Hospital
Study Type
Interventional
Phase
Phase 1/2
Age Eligibility
12 years and older (12year - 17 years separate eligibility)
International registry ID's
NCT05500508
Back to Registry
Study Title AMXT1501-102: A Phase 1B/2A Study of the Safety Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients with Cancer
Protocol ID AMXT1501-102
Disease (Sub Disease) DIPG
DMG
Diagnosis Stage New diagnosis
Relapse/refractory
Location NSW
Sponsor Aminex Therapeutics, Inc. /
Links https://clinicaltrials.gov/study/NCT05500508
Trial Status Open
Trial Open Date 29/11/2022
Sites Sydney Children's Hospital
Study Type Interventional
Phase Phase 1/2
Age Eligibility 12 years and older (12year - 17 years separate eligibility)
International registry ID's NCT05500508

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168

ANZCHOG acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait Islander cultures, and to Elders both past and present. We acknowledge Māori as tangata whenua of Aotearoa New Zealand and as Treaty partners with the Crown as agreed in Te Tiriti o Waitangi. 

We are committed to creating a safe and welcoming environment that embraces all backgrounds, cultures, sexualities, genders and abilities.